S. Küçüködük Et Al. , "Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis," Scandinavian Journal of Infectious Diseases , vol.34, no.12, pp.893-897, 2002
Küçüködük, S. Et Al. 2002. Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis. Scandinavian Journal of Infectious Diseases , vol.34, no.12 , 893-897.
Küçüködük, S., Sezer, T., Yıldıran, A., & Albayrak, D., (2002). Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis. Scandinavian Journal of Infectious Diseases , vol.34, no.12, 893-897.
Küçüködük, Sükrü Et Al. "Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis," Scandinavian Journal of Infectious Diseases , vol.34, no.12, 893-897, 2002
Küçüködük, Sükrü Et Al. "Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis." Scandinavian Journal of Infectious Diseases , vol.34, no.12, pp.893-897, 2002
Küçüködük, S. Et Al. (2002) . "Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis." Scandinavian Journal of Infectious Diseases , vol.34, no.12, pp.893-897.
@article{article, author={Sükrü Küçüködük Et Al. }, title={Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis}, journal={Scandinavian Journal of Infectious Diseases}, year=2002, pages={893-897} }